{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:14:52Z","timestamp":1788052492970,"version":"build-2784847793"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032486","name":"Qatar Research, Development and Innovation Council","doi-asserted-by":"publisher","award":["ARG02-0421-240249"],"award-info":[{"award-number":["ARG02-0421-240249"]}],"id":[{"id":"10.13039\/100032486","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119194","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:39:08Z","timestamp":1785890348000},"page":"119194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives"],"prefix":"10.1016","volume":"318","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-429X","authenticated-orcid":false,"given":"Raed M.","family":"Al-Zoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2848-8698","authenticated-orcid":false,"given":"Alaa","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8489-5873","authenticated-orcid":false,"given":"Basma","family":"Hanbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6747-9927","authenticated-orcid":false,"given":"Sally R.","family":"Al-Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0078-0472","authenticated-orcid":false,"given":"Yosef R.","family":"Al-Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6748-3663","authenticated-orcid":false,"given":"Mohanad","family":"Shkoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4168-8548","authenticated-orcid":false,"given":"Abbas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-9751","authenticated-orcid":false,"given":"Abdelali","family":"Agouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2408-552X","authenticated-orcid":false,"given":"Ameera","family":"Al-Jabiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejmech.2026.119194_bib1","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119194_bib2","article-title":"Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium","volume":"9","author":"Arastehfar","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"165","key":"10.1016\/j.ejmech.2026.119194_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2026.119194_bib5","series-title":"WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action","year":"2022"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/idr17040091","article-title":"Antifungal agents in the 21st century: advances, challenges, and future perspectives","volume":"17","author":"Branda","year":"2025","journal-title":"Infect. Dis. Rep."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10096-004-1228-z","article-title":"Pharmacokinetics\/pharmacodynamics of echinocandins","volume":"23","author":"Theuretzbacher","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s44259-023-00007-2","article-title":"Molecular mechanisms governing antifungal drug resistance","volume":"1","author":"Lee","year":"2023","journal-title":"NPJ Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/MMBR.00045-10","article-title":"Regulatory circuitry governing fungal development, drug resistance, and disease","volume":"75","author":"Shapiro","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119194_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41579-021-00511-0","article-title":"Treatment strategies for cryptococcal infection: challenges, advances and future outlook","volume":"19","author":"Iyer","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019703","article-title":"Antifungal drug development: challenges, unmet clinical needs, and new approaches","volume":"4","author":"Roemer","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119194_bib12","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","volume":"22","author":"Rajasingham","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dkx480","article-title":"A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance","volume":"73","author":"Chowdhary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/jof6040321","article-title":"Amphotericin B and other Polyenes-Discovery, clinical use, mode of action and drug resistance","volume":"6","author":"Carolus","year":"2020","journal-title":"J. Fungi"},{"key":"10.1016\/j.ejmech.2026.119194_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fmicb.2012.00286","article-title":"It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug","volume":"3","author":"Mesa-Arango","year":"2012","journal-title":"Front. Microbiol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejmech.2026.119194_bib18","first-page":"6185","article-title":"Spotlight on tavaborole for the treatment of onychomycosis","volume":"9","author":"Jinna","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib19","first-page":"34","article-title":"Topical treatment for onychomycosis: is it more effective than the clinical data suggests?","volume":"9","author":"Elewski","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2220084","article-title":"Organoboronic acids\/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope","volume":"38","author":"Al-Omari","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1039\/C9MD00139E","article-title":"Recent development of leucyl-tRNA synthetase inhibitors as antimicrobial agents","volume":"10","author":"Zhang","year":"2019","journal-title":"Medchemcomm"},{"issue":"15","key":"10.1016\/j.ejmech.2026.119194_bib22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/mmbr.00187-22","article-title":"Candida auris: host interactions, antifungal drug resistance, and diagnostics","volume":"90","author":"Chowdhary","year":"2026","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/jof7030163","article-title":"Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor","volume":"7","author":"Jallow","year":"2021","journal-title":"J. Fungi"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01541-16","article-title":"Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties","volume":"61","author":"James","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"45","key":"10.1016\/j.ejmech.2026.119194_bib26","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02280-16","article-title":"In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection","volume":"61","author":"Colley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib28","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1128\/AAC.00349-16","article-title":"The investigational drug VT-1129 is a highly potent inhibitor of cryptococcus species CYP51 but only weakly inhibits the human enzyme","volume":"60","author":"Warrilow","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119194_bib29","series-title":"Approval Package for Application Number: 214900Orig1S000. Product Quality Review(S)","year":"2021"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib30","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1111\/1462-2920.14333","article-title":"Enfumafungin synthase represents a novel lineage of fungal triterpene cyclases","volume":"20","author":"Kuhnert","year":"2018","journal-title":"Environ. Microbiol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70362","article-title":"Ibrexafungerp: mechanism of action, clinical, and translational science","volume":"18","author":"Walley","year":"2025","journal-title":"Clin. Transl. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the antifungal activity of the novel oral Glucan Synthase Inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible candida species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02136-19","article-title":"In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01324-23","article-title":"In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains","volume":"68","author":"Aldejohann","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01692-19","article-title":"In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations","volume":"63","author":"Nunnally","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119194_bib37","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp","volume":"72","author":"Marcos-Zambrano","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib38","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib39","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00854-20","article-title":"Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In vivo Guinea pig cutaneous infection model","volume":"64","author":"Ghannoum","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02268-19","article-title":"Penetration of ibrexafungerp (formerly SCY-078) at the site of infection in an intra-abdominal candidiasis mouse model","volume":"64","author":"Lee","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02429-19","article-title":"Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1\u21923)-\u03b2-d-Glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"64","author":"Petraitis","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01545-23","article-title":"Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B","volume":"68","author":"Gebremariam","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00137-25","article-title":"Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains","volume":"69","author":"Ceballos-Garzon","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib45","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkaf133","article-title":"Ibrexafungerp prolongs survival and reduces the eumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma","volume":"80","author":"Ma","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119194_bib46","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/cid\/ciab841","article-title":"Phase 2 randomized study of oral ibrexafungerp versus fluconazole in vulvovaginal candidiasis","volume":"74","author":"Nyirjesy","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib47","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/cid\/ciab750","article-title":"Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303)","volume":"74","author":"Schwebke","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00646-23","article-title":"New perspectives on antimicrobial agents: rezafungin","volume":"69","author":"Forrister","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/00185787231206523","article-title":"Formulary drug review: rezafungin","volume":"59","author":"Kessel","year":"2024","journal-title":"Hosp. Pharm."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib51","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jac\/dkae415","article-title":"The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics","volume":"80","author":"Andes","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1473-3099(23)00627-8","article-title":"New antifungals development: rezafungin in candidiasis treatment","volume":"24","author":"Desnos-Ollivier","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib54","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/infdis\/jiae146","article-title":"Regulatory considerations in the approval of rezafungin (Rezzayo) for the treatment of candidemia and invasive candidiasis in adults","volume":"230","author":"Smith","year":"2024","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib55","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119194_bib56","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/cts.13286","article-title":"A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects","volume":"15","author":"Gu","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf034","article-title":"Long-term safety and effectiveness of rezafungin treatment in candidemia and invasive candidiasis: results from an Early Access Program in Italy and Germany","volume":"12","author":"Trapani","year":"2025","journal-title":"Open Forum Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00253-020-11022-y","article-title":"Echinocandins: structural diversity, biosynthesis, and development of antimycotics","volume":"105","author":"H\u00fcttel","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib59","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/jac\/dky280","article-title":"Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib60","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/jof7090747","article-title":"The long-acting echinocandin, Rezafungin, prevents pneumocystis Pneumonia and eliminates pneumocystis from the lungs in prophylaxis and murine treatment models","volume":"7","author":"Cushion","year":"2021","journal-title":"J. Fungi"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics18020213","article-title":"In vitro activity of rezafungin against planktonic and biofilm forms of Candida albicans and Nakaseomyces glabratus clinical isolates from vascular infections in Poland: a pilot study","volume":"18","author":"Skiba-Kurek","year":"2026","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccc.2010.11.001","article-title":"Fungal sepsis: optimizing antifungal therapy in the critical care setting","volume":"27","author":"Lepak","year":"2011","journal-title":"Crit. Care Clin."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib63","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/fmb.11.19","article-title":"Current perspectives on echinocandin class drugs","volume":"6","author":"Perlin","year":"2011","journal-title":"Future Microbiol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.546","article-title":"Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK\/PD pharmacometrics of rezafungin efficacy","volume":"7","author":"Miesel","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of Rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib68","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01556-19","article-title":"Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib69","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jac\/dkaf124","article-title":"Activity of rezafungin against Candida auris","volume":"80","author":"Locke","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkag058","article-title":"Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro","volume":"81","author":"Abduljalil","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"10370","key":"10.1016\/j.ejmech.2026.119194_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib73","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cpdd.757","article-title":"Lack of effect of rezafungin on QT\/QTc interval in healthy subjects","volume":"9","author":"Flanagan","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib74","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib75","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01339-23","article-title":"Absence of clinically meaningful drug-drug interactions with rezafungin: outcome of investigations","volume":"11","author":"Flanagan","year":"2023","journal-title":"Microbiol. Spectr."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib76","article-title":"Fosmanogepix: the novel anti-fungal agent's comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials","volume":"16","author":"Almajid","year":"2024","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib77","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J. Fungi"},{"issue":"23","key":"10.1016\/j.ejmech.2026.119194_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126713","article-title":"Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against cryptococcus spp","volume":"29","author":"Trzoss","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01623-22","article-title":"Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers","volume":"67","author":"Hodges","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib81","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/jac\/dkad256","article-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial","volume":"78","author":"Pappas","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/jof8080857","article-title":"Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents","volume":"8","author":"Wiederhold","year":"2022","journal-title":"J. Fungi"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib83","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol. Microbiol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib84","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/MMBR.00032-07","article-title":"Candida albicans cell wall proteins","volume":"72","author":"Chaffin","year":"2008","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib85","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/EC.00445-07","article-title":"Ibrahim AS. Gene overexpression\/suppression analysis of candidate virulence factors of Candida albicans","volume":"7","author":"Fu","year":"2008","journal-title":"Eukaryot. Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib86","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum Antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib87","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00425-18","article-title":"Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against Echinocandin- and multidrug-resistant candida isolates in a mouse model of invasive candidiasis","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib89","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diagmicrobio.2011.05.001","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method","volume":"71","author":"Pfaller","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib90","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.00570-11","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods","volume":"55","author":"Pfaller","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.119194_bib91","article-title":"APX001A protects immunosuppressed mice from rhizopus delemar infection","volume":"4","author":"Gebremariam","year":"2017","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib92","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jac\/dkz022","article-title":"In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib93","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits","volume":"65","author":"Petraitiene","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib94","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01120-19","article-title":"Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib95","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus","volume":"64","author":"Gebremariam","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib96","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib97","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkad269","article-title":"Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia","volume":"78","author":"Cornely","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib98","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/jac\/dkad256","article-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial","volume":"78","author":"Pappas","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01419-22","article-title":"Clinical efficacy and safety of a novel Antifungal, Fosmanogepix, in patients with candidemia caused by Candida auris: results from a phase 2 trial","volume":"67","author":"Vazquez","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib100","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1093\/cid\/ciaf185","article-title":"Fosmanogepix for the treatment of invasive mold diseases caused by aspergillus species and rare molds: a Phase 2, Open-Label Study (AEGIS)","volume":"81","author":"Hodges","year":"2025","journal-title":"Clin. Infect. Dis."},{"issue":"suppl_1","key":"10.1016\/j.ejmech.2026.119194_bib101","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx163.1370","article-title":"First-in-Human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects","volume":"4","author":"Hodges","year":"2017","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01455-23","article-title":"Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants","volume":"68","author":"Hodges","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib103","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1186\/s12879-024-10143-3","article-title":"Review of the novel antifungal drug olorofim (F901318)","volume":"24","author":"Vanbiervliet","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119194_bib104","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.bi.49.070180.001345","article-title":"Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis","volume":"49","author":"Jones","year":"1980","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib105","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.FUNK-0035-2016","article-title":"The fungal cell wall: structure, biosynthesis, and function","volume":"5","author":"Gow","year":"2017","journal-title":"Microbiol. Spectr."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib106","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00231-18","article-title":"Effect of the novel antifungal drug F901318 (Olorofim) on growth and viability of Aspergillus fumigatus","volume":"62","author":"du Pr\u00e9","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib107","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa016","article-title":"Hope on the horizon: novel fungal treatments in development","volume":"7","author":"Rauseo","year":"2020","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib108","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02546-20","article-title":"Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China","volume":"65","author":"Su","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib109","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dkz529","article-title":"Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim","volume":"75","author":"Lim","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib110","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs","volume":"62","author":"J\u00f8rgensen","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119194_bib111","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/myc.13273","article-title":"In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes","volume":"64","author":"Badali","year":"2021","journal-title":"Mycoses"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib112","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03304-23","article-title":"Anti-Aspergillus activities of olorofim at sub-MIC levels during early-stage growth","volume":"12","author":"K\u00fchbacher","year":"2024","journal-title":"Microbiol. Spectr."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106105","article-title":"In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus","volume":"56","author":"Kirchhoff","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119194_bib114","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1093\/jac\/dkaa351","article-title":"In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies","volume":"75","author":"Rivero-Menendez","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib115","first-page":"2133","article-title":"Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans","volume":"75","author":"Kirchhoff","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib116","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1093\/jac\/dkae267","article-title":"In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023","volume":"79","author":"Halliday","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib117","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib118","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease","volume":"63","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119194_bib119","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/jac\/dkx065","article-title":"Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans","volume":"72","author":"Wiederhold","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib120","first-page":"1050","article-title":"In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi","volume":"56","author":"Biswas","year":"2018","journal-title":"Med. Mycol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib121","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00999-18","article-title":"The orotomide olorofim is efficacious in an experimental model of central nervous System coccidioidomycosis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib122","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the orotomides against aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"mBio"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119194_bib123","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib124","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1093\/jac\/dky329","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei","volume":"73","author":"Lackner","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib125","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00434-21","article-title":"In vivo efficacy of olorofim against systemic scedosporiosis and lomentosporiosis","volume":"65","author":"Seyedmousavi","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib126","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1093\/jac\/dkaf354","article-title":"In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species","volume":"80","author":"Pinder","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib127","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkag119","article-title":"Comment on: antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus","volume":"81","author":"Pinder","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib128","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00988-24","article-title":"Olorofim demonstrates in vitro activity against Coccidioides species, including isolates against which fluconazole has reduced activity","volume":"69","author":"Wiederhold","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib129","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12348-024-00393-2","article-title":"A case of Lomentospora prolificans endophthalmitis treated with the novel antifungal agent Olorofim","volume":"14","author":"Dong","year":"2024","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib131","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s10875-023-01513-8","article-title":"Prolonged remission of azole-resistant lung aspergillosis with olorofim, in an adolescent with X-Linked chronic granulomatous disease","volume":"43","author":"Michel","year":"2023","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib132","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.690","article-title":"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent","volume":"9","author":"Cass","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib133","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/myc.13335","article-title":"ECMM\/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries","volume":"64","author":"Rudramurthy","year":"2021","journal-title":"Mycoses"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib134","doi-asserted-by":"crossref","first-page":"9482","DOI":"10.1038\/s41598-019-45890-w","article-title":"Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection","volume":"9","author":"Colley","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib135","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dkz280","article-title":"In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris","volume":"74","author":"Rudramurthy","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/jof6040373","article-title":"PC945, a novel inhaled antifungal agent, for the treatment of respiratory fungal infections","volume":"6","author":"Murray","year":"2020","journal-title":"J. Fungi"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119194_bib137","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00124-17","article-title":"In vivo biomarker analysis of the effects of intranasally dosed PC945, a novel antifungal triazole, on Aspergillus fumigatus infection in immunocompromised mice","volume":"61","author":"Kimura","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib138","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bcpt.12820","article-title":"Voriconazole concentrations in plasma and epithelial lining fluid after inhalation and oral treatment","volume":"121","author":"Andersen","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119194_bib139","series-title":"FDA Approves Mycovia Pharmaceuticals' VIVJOA\u2122 (Oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)","author":"Comtois","year":"2022"},{"key":"10.1016\/j.ejmech.2026.119194_bib140","series-title":"VIVJOA\u2122 (Oteseconazole) Capsules, for Oral Use","author":"Pharmaceuticals","year":"2022"},{"key":"10.1016\/j.ejmech.2026.119194_bib141","series-title":"FDA approves Mycovia Pharmaceuticals' VIVJOA\u2122 (oteseconazole), the first and only FDA-Approved medication for recurrent vulvovaginal candidiasis (chronic yeast infection)","year":"2022"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119194_bib142","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib143","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ja.2016.106","article-title":"Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection","volume":"70","author":"Nakamura","year":"2017","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib144","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ja.2016.107","article-title":"ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833","volume":"70","author":"Nakamura","year":"2017","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00163-19","article-title":"Population pharmacokinetic modeling of VL-2397, a novel systemic antifungal agent: analysis of a Single- and multiple-ascending-dose Study in healthy subjects","volume":"63","author":"Kovanda","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib146","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkv398","article-title":"The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata","volume":"71","author":"Wiederhold","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib147","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00969-19","article-title":"First-in-Human phase 1 Study To assess safety, tolerability, and pharmacokinetics of a novel antifungal drug, VL-2397, in healthy adults","volume":"63","author":"Mammen","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib148","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dkq177","article-title":"Uptake of T-2307, a novel arylamidine, in Candida albicans","volume":"65","author":"Nishikawa","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119194_bib149","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 causes collapse of mitochondrial membrane potential in yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/jof6040213","article-title":"Novel antifungal agents and their activity against aspergillus species","volume":"6","author":"Vahedi-Shahandashti","year":"2020","journal-title":"J. Fungi"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.119194_bib151","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/ofid\/ofab466.916","article-title":"Susceptibility testing of oteseconazole (VT-1161) against clinical isolates from phase 3 clinical studies in subjects with recurrent vulvovaginal candidiasis","volume":"8","author":"Ghannoum","year":"2021","journal-title":"Open Forum Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119194_bib152","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02114-18","article-title":"Azole resistance reduces susceptibility to the Tetrazole Antifungal VT-1161","volume":"63","author":"Monk","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib153","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00341-19","article-title":"In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119194_bib154","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01817-16","article-title":"Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01304-19","article-title":"Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib156","article-title":"Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598","volume":"62","author":"Degenhardt","year":"2024","journal-title":"Med. Mycol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119194_bib157","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/AAC.00593-15","article-title":"Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models","volume":"59","author":"Shubitz","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119194_bib158","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02258-17","article-title":"The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119194_bib159","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2217\/fmb-2021-0173","article-title":"Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis","volume":"16","author":"Sobel","year":"2021","journal-title":"Future Microbiol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119194_bib160","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1128\/AAC.01437-15","article-title":"VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection","volume":"59","author":"Gebremariam","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119194_bib161","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100055","article-title":"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis","volume":"1","author":"Sobel","year":"2022","journal-title":"NEJM Evid."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2018.03.001","article-title":"A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis","volume":"218","author":"Brand","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119194_bib164","doi-asserted-by":"crossref","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","article-title":"A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis","volume":"73","author":"Brand","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119194_bib165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bjd.19224","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail","volume":"184","author":"Elewski","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119194_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib167","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119194_bib168","article-title":"Understanding the clinical and environmental drivers of antifungal resistance in the one health context","volume":"170","author":"Williams","year":"2024","journal-title":"Microbiology (Read.)"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119194_bib169","article-title":"Review on current status of echinocandins use","volume":"9","author":"Mroczy\u0144ska","year":"2020","journal-title":"Antibiotics (Basel)"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:15:53Z","timestamp":1788048953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":169,"alternative-id":["S0223523426006392"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119194","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119194"}}